Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing its lead compound, Lucid-MS, toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (MS) following U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application. The clearance represents a significant regulatory milestone for the company and underscores the potential of a novel therapeutic strategy that could alter the treatment landscape for MS, a chronic and often debilitating disease of the central nervous system.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). Unlike current MS therapies that primarily suppress the immune system, Lucid-MS is designed to target demyelination directly—the underlying mechanism of MS. By preventing and reversing myelin degradation, the drug aims to address the root cause of the disease rather than merely managing symptoms. Preclinical models have shown promising results, and the FDA's acceptance of the IND application allows Quantum BioPharma to proceed with clinical testing in humans.
"This IND clearance is a critical step forward in our mission to develop a truly disease-modifying therapy for multiple sclerosis," said a company representative. "Lucid-MS has the potential to be a paradigm shift in how we treat MS, and we are eager to initiate the phase 2 trial." The trial will evaluate the safety and efficacy of Lucid-MS in patients with MS, with the goal of demonstrating a meaningful impact on disease progression.
In addition to the IND clearance, Quantum BioPharma is collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination, which could provide a valuable biomarker for assessing treatment response in MS trials. The collaboration highlights the company's commitment to advancing the understanding and treatment of demyelinating diseases.
The broader biopharmaceutical industry is also witnessing significant advancements in areas of unmet medical need. For instance, Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia, and Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These developments collectively illustrate the dynamic progress across the biotech sector.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS. Quantum also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses. For more information, visit the company's newsroom at https://ibn.fm/QNTM. To view the full press release, visit https://ibn.fm/lCey9.
